The Royal Hobart Hospital is a public hospital in the Hobart CBD, Tasmania, Australia. The hospital also functions as a teaching hospital in co-operation with the University of Tasmania. The hospital's research facilities are known as the Royal Hobart Hospital Research Foundation.

There are 501 beds in Royal Hobart Hospital.

During the past decade, Royal Hobart Hospital conducted 101 clinical trials. In the 10-year time frame, 101 clinical trials started and 47 clinical trials were completed, i.e. on average, 46.5% percent of trials that started reached the finish line to date. In the past 5 years, 46 clinical trials started and 30 clinical trials were completed. i.e. 65.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Royal Hobart Hospital" #1 sponsor was "Hoffmann-La Roche" with 9 trials, followed by "University of Sydney" with 7 trials sponsored, "Australian and New Zealand Intensive Care Research Centre" with 6 trials sponsored, "BeiGene" with 6 trials sponsored and "Celgene" with 6 trials sponsored. Other sponsors include 137 different institutions and companies that sponsored additional 92 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Royal Hobart Hospital" #1 collaborator was "National Health and Medical Research Council, Australia" with 16 trials as a collaborator, "Australian and New Zealand Urogenital and Prostate Cancer Trials Group" with 5 trials as a collaborator, "Bayer" with 5 trials as a collaborator, "Cancer Trials Ireland" with 5 trials as a collaborator and "Australian and New Zealand Intensive Care Society Clinical Trials Group" with 4 trials as a collaborator. Other collaborators include 221 different institutions and companies that were collaborators in the rest 179 trials.

According to Clinical.Site data, the most researched conditions in "Royal Hobart Hospital" are "Pulmonary Arterial Hypertension" (14 trials), "Breast Cancer" (8 trials), "Colorectal Cancer" (4 trials), "Follicular Lymphoma" (4 trials) and "Heart Failure" (4 trials). Many other conditions were trialed in "Royal Hobart Hospital" in a lesser frequency.

Most popular intervention types in "Royal Hobart Hospital" are "Drug" (144 trials), "Other" (22 trials), "Procedure" (13 trials), "Radiation" (13 trials) and "Biological" (12 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (33 trials), "Paclitaxel" (8 trials), "Rituximab" (8 trials), "Venetoclax" (6 trials) and "Bendamustine" (5 trials). Other intervention names were less common.

The vast majority of trials in "Royal Hobart Hospital" are 150 trials for "All" genders, 16 trials for "Female" genders and 10 trials for "Male" genders.

Currently, there are 75 active trials in "Royal Hobart Hospital". 2 are not yet recruiting, 31 are recruiting, 39 are Active, not recruiting, and 3 are Enrolling by invitation. In total, there were 67 completed trials in Royal Hobart Hospital, undefined suspended trials, and 22 terminated clinical trials to date.

Out of the total trials that were conducted in Royal Hobart Hospital, 8 "Phase 1" clinical trials were conducted, 37 "Phase 2" clinical trials and 115 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 13 trials that are defined as “Not Applicable".